ReviewHeart failure reviews2014
Clinical use of novel biomarkers in heart failure: towards personalized medicine.
Review in Heart failure reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review.Heart failure reviews · 2014Pooled it
- Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure.Cardiovascular drugs and therapy · 2017Trial
- From Natriuretic Peptides to microRNAs: Multi-Analyte Liquid Biopsy Horizons in Heart Failure.Biomolecules · 2025Review
- Soluble ST2: A Novel Biomarker for Diagnosis and Prognosis of Cardiovascular Disease.Current medical science · 2024Review
- Article
- The Roles of Exosome-Derived microRNAs in Cardiac Fibrosis.Molecules (Basel, Switzerland) · 2024Review
- New Biomarkers for Cardiovascular Disease.Texas Heart Institute journal · 2023Review
- Pocketable Biosensor Based on Quartz-Crystal Microbalance and Its Application to DNA Detection.Sensors (Basel, Switzerland) · 2022Article
- IL-33/ST2 pathway as upper-hand of inflammation in allergic asthma contributes as predictive biomarker in heart failure.ESC heart failure · 2022Review
- Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study.Journal of the American Heart Association · 2022Article
- Article
- Role of MicroRNAs in Diagnosis, Prognosis, and Treatment of Acute Heart Failure: Ambassadors from Intracellular Zone.Galen medical journal · 2020Review
- The Impact of Cardiac Lipotoxicity on Cardiac Function and Mirnas Signature in Obese and Non-Obese Rats with Myocardial Infarction.Scientific reports · 2019Article
- Significance of non-coding circular RNAs and micro RNAs in the pathogenesis of cardiovascular diseases.Journal of medical genetics · 2018Review
- Reduced exosome miR-425 and miR-744 in the plasma represents the progression of fibrosis and heart failure.The Kaohsiung journal of medical sciences · 2018Article
- Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.Archives of medical science : AMS · 2018Article
- Cardiac molecular imaging to track left ventricular remodeling in heart failure.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Review
- Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.Journal of the American Heart Association · 2017Article
- Article
- Labeling galectin-3 for the assessment of myocardial infarction in rats.EJNMMI research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers play an important role in heart failure. They provide us information about the mechanisms involved in specific types of heart failure and can identify patients at higher risk. Although the majority of biomarker studies in heart failure focus on their prognostic value, the clinical applicability of prognostication in heart failure needs to be established. However, biomarkers can be used for many other purposes. For example, they can help us with the diagnosis of heart failure, and they can be used to select our therapy, leading to personalized tailored therapy. Finally, when biomarkers are causally involved in the disease process, they can even become targets for therapy. The present paper reviews the established and potential value of the novel heart failure biomarkers, mid-regional atrial natriuretic peptide, soluble ST2, growth differentiation factor 15, galectin-3, renal tubular damage markers, and microRNAs. Their potential clinical value will be discussed and compared with the reference markers, the natriuretic peptides.
Indexed as
Identifiers
23709316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.